ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-
First Patient Dosed in Tri-611 Clinical Trial
The first patient has been dosed in the Phase 1/2 clinical trial evaluating TRI-611 for ALK-positive NSCLC, marking an important step forward in the development of new investigational therapies for the ALK-positive community.
-
Nuvalent Announces Submission of New Drug Application to the FDA for Neladalkib (NVL-655) in TKI Pre-treated Advanced ALK-positive NSCLC
Nuvalent has officially filed for FDA approval of NVL-655 (neladalkib), a promising next-generation ALK inhibitor for previously treated ALK-positive lung cancer. Backed by results from the ongoing ALKOVE-1 trial, this milestone could bring a powerful new treatment option one step closer for patients facing progression after prior ALK therapies.
-
-
Continuing ALK NSCLC TKI Treatment while on Chemotherapy Leads to Better Outcomes
A recent multi-center study examined outcomes for ALK-positive NSCLC patients who continued their ALK TKI while receiving platinum/pemetrexed chemotherapy after disease progression. The findings suggest that maintaining targeted therapy alongside chemotherapy may improve overall survival and reduce the risk of brain progression in certain patients.
-
Patient Perspective: Alternative Nuvalent drug for patients disqualified from NVL-655 due to liver toxicity
Jeff Sturm shares his experience accessing the investigational drug zidesamtinib through a single-patient IND after discontinuing the NVL-655 trial due to liver toxicity. His story highlights how physicians, researchers, and companies sometimes work together to explore additional options for patients.
-
Understanding Guardant360 Liquid Biopsy
Guardant360 Liquid is an advanced liquid biopsy that can detect extremely small amounts of tumor DNA circulating in the bloodstream. This technology allows doctors to identify important genetic changes even when tissue biopsies are difficult to obtain.
-
Honoring a Legacy: The John Pender Scholarship Fund
The John Pender Scholarship Fund, established in 2025, honors John’s legacy by supporting students connected to the ALK-positive community who are pursuing higher education. Each year, the scholarship helps a student working toward a future rooted in service, creativity, innovation, or care for others. The inaugural award supported a student pursuing nursing, continuing John’s spirit…
-
-
True or False: Test Your Knowledge of Clinical Trials
Clinical trials are often misunderstood. This short quiz explores common myths and facts about trials, helping patients better understand participation, safety, and the role research plays in improving outcomes for ALK-positive cancers.
-
Patient Spotlight: Nikki Hirsch
After being diagnosed with Stage IV ALK-positive lung cancer in 2021, Nikki Hirsch found strength through community, advocacy, and connection. From leading the Single ALKies sessions on ALKtALK to organizing community fundraisers, Nikki shares how staying informed, supporting others, and finding joy in everyday moments help her navigate life with hope.
-
ALK Positive Grants Support Dr. Alice Shaw’s Pioneering ALK-Positive Lung Cancer Research
ALK Positive is proud to support Dr. Alice Shaw’s pre-clinical research advancing the understanding of ALK-positive lung cancer. Her work focuses on uncovering biological mechanisms that drive treatment resistance, with the goal of informing future therapeutic strategies and improving long-term outcomes for patients. Through this partnership, ALK Positive is investing in science that accelerates progress…
-
ALK Positive and Pfizer Announce New Grant Opportunity to Improve Education and Support for People Living With Advanced ALK+ Lung Cancer
We’re proud to partner with Pfizer on a new grant opportunity designed to strengthen education for people diagnosed with advanced ALK-positive lung cancer. This RFP supports independent projects that help patients and care partners prepare for treatment, recognize side effects early, and access clear, inclusive resources that honor their preferences. Funding is available for organizations…